Literature DB >> 7757977

Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved.

E Wang1.   

Abstract

Programmed cell death (apoptosis) is an active process by which cells initiate their own self-destruction. Growing evidence shows that this event is controlled by the activation of unique gene expression; some function as survival genes, such as bcl2, and others as killer genes, such as ced3 or interleukin converting enzyme. Likewise, external factors, such as the presence or absence of stimuli in the microenvironment of a cell, play a key role in ushering it towards survival or suicidal fate. Previously, I and others have reported that withdrawal of serum from culture medium can induce contact-inhibited quiescent mouse 3T3 fibroblasts to undergo rapid programmed cell death, as evidenced by the presence of massive DNA fragmentation within 24 h. I now report that, although the same process of serum withdrawal is capable of inducing apoptotic death in quiescent young human fibroblasts, the process takes as long as 2 weeks. Repeated attempts at the same serum withdrawal with cultures of senescent human fibroblasts show that phenotypic signs of apoptosis, such as DNA fragmentation and loss of cell viability, are not observed for up to 4 weeks; I suggest that in vitro aged human fibroblasts are resistant to undergoing programmed cell death. I have investigated the level of bcl2 presence as a possible protector of senescent human fibroblasts from apoptotic death; biochemical characterization shows that in mouse as well as human fibroblasts, bcl2 is present as an easily extractable (0.1% Triton) cytoplasmic protein. bcl2 level is in inverse relationship with the ease of induction of apoptotic death between young and senescent human fibroblasts. Immunofluorescence staining shows that, in senescent human fibroblasts, bcl2 is present not only in the cytoplasmic punctate spots seen in both mouse and young human fibroblasts but also in the nuclei as well as large granules surrounding the nuclei. Upon serum deprivation, the bcl2 level is reduced to undetectable in mouse 3T3 fibroblasts within 24 h and in young and intermediate aged human fibroblasts within 2 weeks; however, it remains unchanged in senescent human fibroblasts after the deprivation of serum for 2 weeks. These findings lead me to conclude that senescent fibroblasts are resistant to the induction of apoptotic death by serum deprivation. Furthermore, I suggest that repeated serial passaging during the in vitro aging process has inadvertently instituted a molecular mechanism whereby the bcl2 level cannot be repressed upon serum deprivation, which may subsequently allow senescent fibroblasts to be long-lived and protected from self-destruction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7757977

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  136 in total

Review 1.  The immune system in the elderly: II. Specific cellular immunity.

Authors:  L Ginaldi; M De Martinis; A D'Ostilio; L Marini; M F Loreto; V Martorelli; D Quaglino
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53.

Authors:  A Seluanov; V Gorbunova; A Falcovitz; A Sigal; M Milyavsky; I Zurer; G Shohat; N Goldfinger; V Rotter
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Authors:  Anna E Vilgelm; Jeff S Pawlikowski; Yan Liu; Oriana E Hawkins; Tyler A Davis; Jessica Smith; Kevin P Weller; Linda W Horton; Colt M McClain; Gregory D Ayers; David C Turner; David C Essaka; Clinton F Stewart; Jeffrey A Sosman; Mark C Kelley; Jeffrey A Ecsedy; Jeffrey N Johnston; Ann Richmond
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

4.  PKB phosphorylation and survivin expression are cooperatively regulated by disruption of microfilament cytoskeleton.

Authors:  Yu-Long Liang; Li-Ying Wang; Heng Wu; Dong-Zhu Ma; Zhen Xu; Xi-Liang Zha
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

Review 5.  Cellular senescence in cancer treatment: friend or foe?

Authors:  Pascal Kahlem; Bernd Dörken; Clemens A Schmitt
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

6.  Bcl-2 activates a programme of premature senescence in human carcinoma cells.

Authors:  Elvira Crescenzi; Giuseppe Palumbo; Hugh J M Brady
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

Review 7.  The immune system in the elderly: activation-induced and damage-induced apoptosis.

Authors:  Lia Ginaldi; Massimo De Martinis; Daniela Monti; Claudio Franceschi
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 8.  Apoptosis and aging: increased resistance to apoptosis enhances the aging process.

Authors:  Antero Salminen; Johanna Ojala; Kai Kaarniranta
Journal:  Cell Mol Life Sci       Date:  2010-11-30       Impact factor: 9.261

9.  The Clinical Potential of Senolytic Drugs.

Authors:  James L Kirkland; Tamara Tchkonia; Yi Zhu; Laura J Niedernhofer; Paul D Robbins
Journal:  J Am Geriatr Soc       Date:  2017-09-04       Impact factor: 5.562

10.  WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway.

Authors:  Romuald Binet; Damien Ythier; Ana I Robles; Manuel Collado; Delphine Larrieu; Claire Fonti; Elisabeth Brambilla; Christian Brambilla; Manuel Serrano; Curtis C Harris; Rémy Pedeux
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.